Japanese flu treatment 'Avigan' to apply for COVID-19 treatment approval next month
![[Image source=Yonhap News]](http://www.asiae.co.kr/news/img_view.htm?img=2020040513113159945_1586059890.jpg)
[Asia Economy Reporter Cho Hyun-ui] Toyama Chemical, a subsidiary of Fujifilm, announced on the 23rd that it plans to apply for approval of its newly developed influenza treatment drug 'Avigan' as a treatment for the novel coronavirus infection (COVID-19) next month.
According to NHK, the company announced that it confirmed the efficacy of Avigan through clinical trials administering the drug to COVID-19 patients.
The company explained that in a comparison of the period until symptom improvement and a negative result in genetic testing (PCR) among 156 COVID-19 patients aged 20 to 74, the Avigan-administered group took 11.9 days, about 3 days shorter than the 14.7 days in the non-administered group.
They added that aside from previously known side effects such as decreased kidney and liver function, no new safety concerns were observed.
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If a Samsung Electronics Employee with a 100 Million Won Salary Receives a 600 Million Won Performance Bonus, Taxes Total 247.19 Million Won
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- "Iran Rapidly Rebuilding Military... Drone Capabilities to Be Restored Within Six Months"
- "4.15 Million Won Prada Jacket Shows White Spots After One Wear"...Korea Consumer Agency Orders Full Refund
Accordingly, the company decided to apply to the relevant Japanese authorities next month for approval of Avigan as a COVID-19 treatment.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
